paroxetine has been researched along with selegiline in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Graham, D; Langer, SZ; Tahraoui, L | 1 |
| Nichols, DE; Sprague, JE | 1 |
| Iacono, RP; Toyama, SC | 1 |
| Andrews, AM; Murphy, DL | 1 |
| Johnson, MP; Nichols, DE; Schmidt, CJ; Sprague, JE | 1 |
| Carey, GJ; Gold, LH; Nielsen, DM | 1 |
| Deng, JF; Wu, ML | 1 |
2 review(s) available for paroxetine and selegiline
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for paroxetine and selegiline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat.
Topics: Animals; Cerebral Cortex; Citalopram; Clomipramine; Clorgyline; Kinetics; Male; Membranes; Monoamine Oxidase Inhibitors; Paroxetine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Selegiline; Serotonin | 1987 |
Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum.
Topics: Animals; Corpus Striatum; Hydroxyindoleacetic Acid; Male; Monoamine Oxidase Inhibitors; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Sprague-Dawley; Selegiline; Serotonin; Sodium Chloride | 1995 |
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline | 1994 |
2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neuro
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Clorgyline; Desipramine; Fluoxetine; Hippocampus; Male; Mice; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neurotransmitter Uptake Inhibitors; Norepinephrine; Paroxetine; Selegiline; Serotonin; Serotonin Receptor Agonists; Synaptic Transmission; Time Factors | 1993 |
Studies on the mechanism of p-chloroamphetamine neurotoxicity.
Topics: Animals; Brain; Clorgyline; Dopamine; Fever; Hydroxyindoleacetic Acid; Indans; Male; Monoamine Oxidase Inhibitors; N-Methyl-3,4-methylenedioxyamphetamine; Neuroprotective Agents; Neurotoxins; p-Chloroamphetamine; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin; Serotonin Agents | 1996 |
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Topics: Animals; Antidepressive Agents; Clorgyline; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Hindlimb Suspension; Male; Mice; Morpholines; Motor Activity; Paroxetine; Pyrazoles; Pyrimidines; Pyrroles; Reboxetine; Receptors, Corticotropin-Releasing Hormone; Selegiline; Swimming; Tranylcypromine; Triazines | 2004 |
Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline.
Topics: Female; Humans; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Paroxetine; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin | 2009 |